About Firapy
Firapy is a company based in Taipei (Taiwan) founded in 1991. It operates as a B2B. Firapy offers products and services including TY-101F, TY-102F, KP-B210, and KP-B220. Firapy operates in a competitive market with competitors including TISSIUM, Cardival Medical, Laminate Medical, Aziyo Biologics and Vivasure Medical, among others.
- Headquarter Taipei, Taiwan
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website firapy.com
- Legal Name Ws Far Ir Medical Technology
Products & Services of Firapy
Firapy offers a comprehensive portfolio of products and services, including TY-101F, TY-102F, KP-B210, and KP-B220.
Device for reducing vascular access problems and improving blood flow.
Unit that aids in vascular tissue repair and vasodilation.
Therapy device for peripheral artery occlusive disease treatment.
Unit focused on wound healing and vascular applications.
Competitors of Firapy
Firapy operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TISSIUM, Cardival Medical, Laminate Medical, Aziyo Biologics and Vivasure Medical, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tissium.com | 2013 | Paris, France | $155.98M | – | Vascular sealants for open surgery are developed by TISSIUM. | |
| cardivamedical.com | 2002 | Santa Clara, United States | $169.45M | 158 | A device for vascular access management is developed. | |
| laminatemedical.com | 2012 | Rehovot, Israel | $20M | – | AV fistula maturation and patency are supported by VasQ device. | |
| aziyo.com | 2015 | Silver Spring, United States | $49.59M | 162 | Regenerative medicine products are developed for orthopedic and cardiovascular applications. | |
| vivasuremedical.com | 2009 | Galway, Ireland | $92.08M | – | Bioabsorbable implants and delivery systems for arteriotomy closure are developed. | |
| ekoscorp.com | 1995 | Bothell, United States | $58.8M | – | Ultrasound thrombolytic devices for pulmonary embolism treatment are developed. | |
| saranas.com | 2011 | Houston, United States | $29.46M | – | A device is developed for detecting internal bleeding during catheterization. | |
| accessvascularinc.com | 2015 | Bedford, United States | $54.29M | – | Hydrogel-based devices are developed for improved venous access. | |
| tvamedical.com | 2009 | Austin, United States | $27.37M | – | Minimally invasive endovascular therapies for end-stage renal disease are developed. | |
| semprusbio.com | 2006 | Cambridge, United States | $26M | – | Bio-functional surfaces are provided for implantable medical devices. |
Detailed competitors of Firapy
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Firapy
10 companies that operate in the same segment as Firapy (Wound Care), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanotech-based wound care products are developed and provided. | 2010 | Madison, Wisconsin, United States | USD 22.7 M | – | 35 | |
Fish-skin acellular dermal matrix technology is provided for wound treatments. | 2007 | Isafjordur, Iceland | USD 93.11 M | – | 150 | |
Developer of advanced haemostat and wound care dressing products | 2008 | Ahmedabad, Gujarat, India | USD 42.71 M | USD 2.88 M | 70 | |
Oxygen-based wound therapy devices are developed for healing non-healing wounds. | 2003 | Waterbeach, Cambridgeshire, United Kingdom | USD 68.39 M | – | – | |
Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics | 1985 | Marietta, Georgia, United States | – | USD 418.63 M | 837 | |
Biological drugs for skin and mucosa wound treatment are developed. | 2016 | Uppsala, Uppsala County, Sweden | USD 4.02 M | USD 1.12 M | – | |
Developer of hemostatic products for wound care | 2010 | New York, New York, United States | USD 113.35 M | – | – | |
Regenerative therapies for wound care are developed and commercialized. | 1985 | Canton, Ohio, United States | USD 30 M | USD 564.17 M | 869 | |
Cold plasma solutions for wound treatment are developed. | 2013 | Eindhoven, Noord-brabant, Netherlands | USD 7.06 M | – | – | |
Point-of-care devices for wound bacterial assessment are provided. | 2013 | Toronto, Ontario, Canada | USD 43.2 M | – | 49 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Firapy
Firapy was founded in 1991.
Firapy is headquartered in Taipei, Taiwan.
FIRAPY develops and supplies far-infrared therapy units that enhance vasodilation, blood flow, and tissue repair, primarily for vascular access, peripheral artery occlusive disease, and wound treatment. The company operates through medical device distribution and partnerships with hospitals and distributors globally. Based in New Taipei City, Taiwan, it focuses on clinical applications supported by scientific publications and guidelines from organizations like ERA-EDTA. Products are marketed for medical professionals to address health issues effectively.
Firapy's top competitors include TISSIUM, Vivasure Medical and Cardival Medical.
Firapy offers TY-101F, TY-102F, KP-B210, and KP-B220.
Firapy operates through Ws Far Ir Medical Technology.